Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF : clinical practice guidelines for the use of G-CSF 2022
© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology..
BACKGROUND: Docetaxel (DTX) is commonly used as a primary chemotherapy, and cabazitaxel (CBZ) has shown efficacy in patients who are DTX resistant. Primary prophylactic granulocyte colony stimulating factor (G-CSF) therapy is currently used with CBZ treatment in routine clinical care in Japan.
METHODS: In this study, we performed a systematic review following the Minds guidelines to investigate the effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for prostate cancer and to construct G-CSF guidelines for primary prophylaxis use during chemotherapy. A comprehensive literature search of various electronic databases (PubMed, Cochrane Library, and Ichushi) was performed on January 10, 2020, to identify studies published between January 1990 and December 31, 2019 that investigate the impact of primary prophylaxis with G-CSF during CBZ administration on clinical outcomes.
RESULTS: Ultimately, nine articles were included in the qualitative systematic review. Primary G-CSF prophylaxis during CBZ administration for metastatic castration-resistant prostate cancer was difficult to assess in terms of correlation with overall survival, mortality from infection, and patients' quality of life. These difficulties were owing to the lack of randomized controlled trials comparing patients with and without primary prophylaxis of G-CSF during CBZ administration. However, some retrospective studies have suggested that it may reduce the incidence of febrile neutropenia.
CONCLUSION: G-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a "weak recommendation to perform" with an annotation of the relevant regimen.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
International journal of clinical oncology - 29(2024), 5 vom: 27. Apr., Seite 559-563 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kimura, Shoji [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
143011-72-7 |
|---|
| Anmerkungen: |
Date Completed 25.04.2024 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10147-024-02501-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370285050 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370285050 | ||
| 003 | DE-627 | ||
| 005 | 20240427232206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10147-024-02501-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1390.xml |
| 035 | |a (DE-627)NLM370285050 | ||
| 035 | |a (NLM)38538963 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kimura, Shoji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF |b clinical practice guidelines for the use of G-CSF 2022 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2024 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology. | ||
| 520 | |a BACKGROUND: Docetaxel (DTX) is commonly used as a primary chemotherapy, and cabazitaxel (CBZ) has shown efficacy in patients who are DTX resistant. Primary prophylactic granulocyte colony stimulating factor (G-CSF) therapy is currently used with CBZ treatment in routine clinical care in Japan | ||
| 520 | |a METHODS: In this study, we performed a systematic review following the Minds guidelines to investigate the effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for prostate cancer and to construct G-CSF guidelines for primary prophylaxis use during chemotherapy. A comprehensive literature search of various electronic databases (PubMed, Cochrane Library, and Ichushi) was performed on January 10, 2020, to identify studies published between January 1990 and December 31, 2019 that investigate the impact of primary prophylaxis with G-CSF during CBZ administration on clinical outcomes | ||
| 520 | |a RESULTS: Ultimately, nine articles were included in the qualitative systematic review. Primary G-CSF prophylaxis during CBZ administration for metastatic castration-resistant prostate cancer was difficult to assess in terms of correlation with overall survival, mortality from infection, and patients' quality of life. These difficulties were owing to the lack of randomized controlled trials comparing patients with and without primary prophylaxis of G-CSF during CBZ administration. However, some retrospective studies have suggested that it may reduce the incidence of febrile neutropenia | ||
| 520 | |a CONCLUSION: G-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a "weak recommendation to perform" with an annotation of the relevant regimen | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Cabazitaxel | |
| 650 | 4 | |a G-CSF | |
| 650 | 4 | |a Neutropenia | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 7 | |a cabazitaxel |2 NLM | |
| 650 | 7 | |a 51F690397J |2 NLM | |
| 650 | 7 | |a Docetaxel |2 NLM | |
| 650 | 7 | |a 15H5577CQD |2 NLM | |
| 650 | 7 | |a Granulocyte Colony-Stimulating Factor |2 NLM | |
| 650 | 7 | |a 143011-72-7 |2 NLM | |
| 650 | 7 | |a Taxoids |2 NLM | |
| 700 | 1 | |a Shigeta, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Tamura, Shingo |e verfasserin |4 aut | |
| 700 | 1 | |a Uchino, Keita |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ozaki, Yukinori |e verfasserin |4 aut | |
| 700 | 1 | |a Nishio, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuchihashi, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Ichihara, Eiki |e verfasserin |4 aut | |
| 700 | 1 | |a Endo, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Yano, Shingo |e verfasserin |4 aut | |
| 700 | 1 | |a Maruyama, Dai |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshinami, Tetsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Susumu, Nobuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Takekuma, Munetaka |e verfasserin |4 aut | |
| 700 | 1 | |a Motohashi, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Mamoru |e verfasserin |4 aut | |
| 700 | 1 | |a Baba, Eishi |e verfasserin |4 aut | |
| 700 | 1 | |a Ochi, Nobuaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kubo, Toshio |e verfasserin |4 aut | |
| 700 | 1 | |a Kamiyama, Yutaro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakao, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Tamura, Shinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimoto, Hitomi |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Yasuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Takano, Toshimi |e verfasserin |4 aut | |
| 700 | 1 | |a Miura, Yuji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical oncology |d 1997 |g 29(2024), 5 vom: 27. Apr., Seite 559-563 |w (DE-627)NLM095566163 |x 1437-7772 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:5 |g day:27 |g month:04 |g pages:559-563 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10147-024-02501-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 5 |b 27 |c 04 |h 559-563 | ||